Abstract: A system for exchanging data between applications is disclosed. In an example embodiment, a printer communicatively coupled with a first application prints a plurality of codes, which are affixed to a plurality of loads. A second application later scans codes affixed to loads. Based on the scanned codes, the second application generates an aggregate code that encodes identifiers of the loads. The second application displays the aggregate code on a screen, and the first application may scan the displayed aggregate code. The first application may compare identifiers encoded by the aggregate code with a list of identifiers to determine whether the second application ingested all expected identifiers.

Abstract: Disclosed herein are compounds of Formulae I or II, or an isotopically enriched compound thereof, or a pharmaceutically acceptable salt thereof, methods for making the compounds, and methods for their use.

Abstract: Disclosed herein are compounds of the formula as well as methods for their use in treating neurologic and brain disorders.

Abstract: Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Disclosed herein are isotopically enriched compounds of 2-bromolysergic acid diethylamide, LSD, ALD-52, and 1P-LSD, as well as methods for their use in treating neurologic and brain disorders.

Abstract: A system for exchanging data between applications is disclosed. In an example embodiment, a printer communicatively coupled with a first application prints a plurality of codes, which are affixed to a plurality of loads. A second application later scans codes affixed to loads. Based on the scanned codes, the second application generates an aggregate code that encodes identifiers of the loads. The second application displays the aggregate code on a screen, and the first application may scan the displayed aggregate code. The first application may compare identifiers encoded by the aggregate code with a list of identifiers to determine whether the second application ingested all expected identifiers.

Abstract: Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Disclosed herein are compounds of the formula as well as methods for their use in treating neurologic and brain disorders.

Abstract: Disclosed examples generally relate to an antenna using embedded metamaterial based electromagnetic bandgap (MTM-EBGs) unit cells, and a method of fabricating thereof. In some examples, the antenna structure comprises: an inner patch; a plurality of metamaterial based electromagnetic bandgap (MTM-EBG) unit cells disposed along an outer perimeter of the inner patch, each unit cell being configurable between an activated state and a deactivated state, each unit cell comprising a two layer parallel plate capacitive arrangement defined by, a dielectric substrate extending between a first surface and a second surface along an extension axis, two first capacitive plates fabricated along the first surface and separated by a gap, and a second capacitive plate fabricated along the second surface and overlapping with the first capacitive plates in a direction along the extension axis.

Abstract: Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Systems, apparatuses, and methods for more effectively monitoring social network and social media posts to assist in identifying posted video, audio, or textual content that may be of interest or concern to a specific entity. This may comprise implementation of a process or technique to select a platform to extract content from, selecting one or more channels or sub-channels on that platform from which to extract content of interest or concern, identifying and subsequently extracting posts expected to contain content of interest or concern, post-processing the extracted content to place it into a form in which it can better be evaluated, and based on the extracted and processed content, causing one or more actions or events to occur.

Abstract: A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to Parkinson's disease.

Abstract: Disclosed herein are isotopically enriched compounds and methods of using both isotopically and non-isotopically enriched compounds of the following formula in the treatment of neurologic and brain disorders/conditions.

Abstract: A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to one or more neurological conditions. To support these applications, the present disclosure accurately determines the normative range of neuromelanin-sensitive MRI signal and volume metrics in cognitively normal older adults. Those displaying certain characteristic neuromelanin-sensitive MRI signals falling outside of the normative range should be assessed and treated according to the particular diagnosis as provided by the present application.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: Deuterated forms of idazoxan according to Formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: Certain aspects of the present disclosure include compounds having Formula (X). Disclosed embodiments also include compositions comprising at least one compound according to the present disclosure, such as from 5% to 70% of at least one compound according to the present disclosure, at a dosage of from 0.1 mg to about 10,000 mg, and further comprising an excipient, an adjuvant, a carrier, and/or at least one additional biologically active compound other than a compound according to the present disclosure. Disclosed compounds and/or can be administered to a subject multiple times per day, such as 1 to 3 times per day, and/or periodically, such as every 2 to 7 days, for a variety of reasons, such as to increase neuronal plasticity, to treat a neurological disease, to treat a neuropsychiatric disease, to elicit a biological response, such as by activating a 5-HT2A receptor, or to increase at least one of translation, transcription, or secretion of neurotrophic factors.

Abstract: The present disclosure relates to compounds Formula (I): methods for making the compounds and methods for their use.